A record to read carefully

Tesamorelin: evidence profile

Approved product · Randomized evidence

Status recorded · Page published

Read the product, route and approval scope together. A category label does not replace those details. Use the exercise to prepare questions, not to choose a treatment.

Evidence record

Product and route
Specified subcutaneous formulation.
Approval scope
Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Mechanism
Stimulates growth-hormone release.
Evidence
A randomized trial measured visceral fat.
Limits
Not for weight management.
Safety context
Active malignancy is a contraindication.

Try this while reading

A dash in a tesamorelin table is a place to pause, not a value to interpret. Check the table key for what the symbol means and whether the report explains why that entry is absent. Make a small list of unresolved entries, keeping each row label and visit date attached. A recorded value described as normal belongs on a different list from an entry with no recorded value. Before summarizing the table, check that your wording keeps those lists apart. If the key does not explain a gap, carry the uncertainty forward as a question about documentation rather than supplying a reassuring answer.

Questions to keep

  1. How does the table key define the dash or blank in this row?
  2. Is there a recorded value behind the description normal?
  3. Which unresolved row and visit should I identify when asking for clarification?

Sources to open

Checked dates belong to the linked records, rather than to this page's publication.

  1. EGRIFTA WR — NLM; checked
  2. Falutz trial — PubMed; checked